Anadys Lands Lucrative HCV Deal with Novartis
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 61 (Table of Contents)
Published: 1 Jul-2005
DOI: 10.3833/pdr.v2005.i61.654 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Anadys Pharmaceuticals has secured Novartis as a global co-development, and potentially co-promotion, partner for ANA975, its promising Phase I therapy for chronic HCV infections...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS